Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 33

1.

Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence.

Etzioni R, Gulati R.

Med Care. 2013 Apr;51(4):304-6. doi: 10.1097/MLR.0b013e31828a7e1a.

PMID:
23481032
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.

Carter HB.

BJU Int. 2013 Sep;112(5):543-7. doi: 10.1111/bju.12318. Review.

PMID:
23924423
[PubMed - indexed for MEDLINE]
3.

American Cancer Society guideline for the early detection of prostate cancer: update 2010.

Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA; American Cancer Society Prostate Cancer Advisory Committee.

CA Cancer J Clin. 2010 Mar-Apr;60(2):70-98. doi: 10.3322/caac.20066. Epub 2010 Mar 3. Review.

PMID:
20200110
[PubMed - indexed for MEDLINE]
Free Article
4.

Screening for prostate cancer.

Ilic D, Neuberger MM, Djulbegovic M, Dahm P.

Cochrane Database Syst Rev. 2013 Jan 31;1:CD004720. doi: 10.1002/14651858.CD004720.pub3. Review.

PMID:
23440794
[PubMed - indexed for MEDLINE]
5.

Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts.

Rove KO, Crawford ED.

World J Urol. 2012 Apr;30(2):137-42. doi: 10.1007/s00345-011-0799-4. Epub 2011 Nov 25. Review.

PMID:
22116599
[PubMed - indexed for MEDLINE]
6.

Screening for prostate cancer: the current evidence and guidelines controversy.

Gomella LG, Liu XS, Trabulsi EJ, Kelly WK, Myers R, Showalter T, Dicker A, Wender R.

Can J Urol. 2011 Oct;18(5):5875-83. Review.

PMID:
22018148
[PubMed - indexed for MEDLINE]
Free Article
7.

PSA screening: a public health dilemma.

Mandelson MT, Wagner EH, Thompson RS.

Annu Rev Public Health. 1995;16:283-306. Review.

PMID:
7543756
[PubMed - indexed for MEDLINE]
8.

Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials.

Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, Dahm P.

BMJ. 2010 Sep 14;341:c4543. doi: 10.1136/bmj.c4543. Review.

PMID:
20843937
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Schröder FH.

Can J Urol. 2005 Feb;12 Suppl 1:2-6; discussion 92-3. Review.

PMID:
15780157
[PubMed - indexed for MEDLINE]
10.

Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.

Lim LS, Sherin K; ACPM Prevention Practice Committee.

Am J Prev Med. 2008 Feb;34(2):164-70. doi: 10.1016/j.amepre.2007.10.003. Review. Erratum in: Am J Prev Med. 2008 May;34(5):454.

PMID:
18201648
[PubMed - indexed for MEDLINE]
11.

Enhancing the use and quality of colorectal cancer screening.

Holden DJ, Harris R, Porterfield DS, Jonas DE, Morgan LC, Reuland D, Gilchrist M, Viswanathan M, Lohr KN, Lyda-McDonald B.

Evid Rep Technol Assess (Full Rep). 2010 Feb;(190):1-195, v. Review.

PMID:
20726624
[PubMed - indexed for MEDLINE]
Free Article
12.

Screening for prostate cancer is neither appropriate nor cost-effective.

Albertsen PC.

Urol Clin North Am. 1996 Nov;23(4):521-30. Review.

PMID:
8948407
[PubMed - indexed for MEDLINE]
13.

NIH state-of-the-science conference statement: Enhancing use and quality of colorectal cancer screening.

Steinwachs D, Allen JD, Barlow WE, Duncan RP, Egede LE, Friedman LS, Keating NL, Kim P, Lave JR, LaVeist TA, Ness RB, Optican RJ, Virnig BA.

NIH Consens State Sci Statements. 2010 Feb 4;27(1):1-31. Review.

PMID:
20140035
[PubMed - indexed for MEDLINE]
Free Article
14.

Rationale for randomised trials of prostate cancer screening. The International Prostate Screening Trial Evaluation Group.

[No authors listed]

Eur J Cancer. 1999 Feb;35(2):262-71. Review.

PMID:
10448269
[PubMed - indexed for MEDLINE]
15.

Prostate cancer screening: what we have learned from the PLCO and ERSPC trials.

La Rochelle J, Amling CL.

Curr Urol Rep. 2010 May;11(3):198-201. doi: 10.1007/s11934-010-0109-5. Review.

PMID:
20425627
[PubMed - indexed for MEDLINE]
16.

Screening for prostate cancer: the roles of science, policy, and opinion in determining what is best for patients.

Woolf SH, Rothemich SF.

Annu Rev Med. 1999;50:207-21. Review.

PMID:
10073273
[PubMed - indexed for MEDLINE]
17.

Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force.

Lin K, Lipsitz R, Miller T, Janakiraman S; U.S. Preventive Services Task Force.

Ann Intern Med. 2008 Aug 5;149(3):192-9. Review.

PMID:
18678846
[PubMed - indexed for MEDLINE]
18.

Risk stratification in prostate cancer screening.

Roobol MJ, Carlsson SV.

Nat Rev Urol. 2013 Jan;10(1):38-48. doi: 10.1038/nrurol.2012.225. Epub 2012 Dec 18. Review. Erratum in: Nat Rev Urol. 2013 May;10(5):248.

PMID:
23247693
[PubMed - indexed for MEDLINE]
19.

Screening for skin cancer: an update of the evidence for the U.S. Preventive Services Task Force.

Wolff T, Tai E, Miller T.

Ann Intern Med. 2009 Feb 3;150(3):194-8. Review.

PMID:
19189909
[PubMed - indexed for MEDLINE]
20.

The benefits and harms of breast cancer screening: an independent review.

Independent UK Panel on Breast Cancer Screening.

Lancet. 2012 Nov 17;380(9855):1778-86. doi: 10.1016/S0140-6736(12)61611-0. Epub 2012 Oct 30. Review.

PMID:
23117178
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk